Frame Bio Secures Licensing for Innovative Drug Delivery Technology to Aid Regenerative Medicine

Frame Bio's Innovative Partnership with Mercury Bio

Frame Bio, a biotechnology pioneer, has taken a significant step forward in regenerative medicine by securing an exclusive licensing agreement with Mercury Bio. This collaboration will leverage Mercury Bio's innovative extracellular vesicle (EV) drug delivery technology, known as yEV™, designed specifically for targeted therapy distribution. By encapsulating therapeutic agents in a unique subset of EVs called exosomes, this platform has the potential to revolutionize treatment for structural diseases and disorders.

The Power of yEV™ Technology

Exosomes naturally facilitate cellular communication, acting as a transport mechanism for various biological molecules. By utilizing customized targeting ligands, the yEV™ technology allows for the direct delivery of therapeutic packages to specific cells with enhanced potency. This tailored approach aims to minimize side effects compared to traditional delivery methods, thereby transforming how therapies for bone and collagen diseases are administered.

The licensing agreement enables Frame Bio to explore a wide array of regenerative therapies aimed at hastening bone healing and restoring collagen integrity. Moreover, Frame Bio's access to Mercury Bio's rich research and development resources will facilitate IND-enabling activities, a critical step in advancing new treatments toward clinical use.

Focus on Bone Healing and Collagen Restoration

Frame Bio's collaboration is set to propel innovative solutions in bone regeneration. For instance, the integration of hydroxyapatite— a naturally occurring calcium compound found in bones— with the yEV™ delivery system aims to enhance the binding of osteo-inductive proteins at injury sites. Proteins like BMP-2, which are already FDA-approved to assist in certain fracture healing and spinal fusion procedures, will be employed in these new therapeutic candidates.

Equally important is Frame Bio's ambition in collagen regeneration, targeting one of the most abundant proteins in the human body that plays a vital role in skin, connective tissue, and organ structure. With aging linked to collagen depletion, the company's fresh approaches intend to combat the reduction in skin and joint integrity, providing solutions that address the fundamental causes of discomfort and injury rather than simply managing symptoms.

Currently, both therapeutic initiatives are gearing towards mRNA payload delivery directly to affected areas and will remain in the pre-clinical research stage over the upcoming year. Concurrently, Frame Bio plans to expand its product portfolio through strategic partnerships with other pharmaceutical firms that specialize in treatments for musculoskeletal conditions.

About Frame Bio

Founded in 2024 with initial funding from Barson Corporation, Frame Bio is dedicated to developing therapies that target skin-bone relationships—highlighting the interdependence of these systems in overall health. The company seeks to set a precedent in treating ailments that affect both skin and bones through innovative research in collagen regeneration, accelerated healing, and inflammation management.

About Mercury Bio

Emerging from groundbreaking genomic research, Mercury Bio has established itself with a next-generation biomolecular drug delivery system. By prioritizing patient safety and drug efficacy, their unique approach employs cell-specific targeting mechanisms, significantly enhancing the impact of therapeutic agents while lowering adverse effects. This scalable and cost-effective platform unlocks a new realm of possibilities for protein and RNA therapeutics for patients worldwide.

Frame Bio's licensing agreement with Mercury Bio not only indicates a promising future for regenerative medicine but also highlights the continuous innovation and collaboration driving advancements in healthcare.